@article{d93aa9b7bbad40ddb0c7e5d82bc3dd1e,
title = "Atezolizumab in “Real World” Patients: Do Phase 3b Trials Help Bridge the Gap Between Efficacy and Effectiveness?",
author = "Patel, {Vaibhav G.} and Galsky, {Matthew D.}",
note = "Funding Information: Conflicts of interest: Vaibhav G. Patel has nothing to disclose. Matthew D. Galsky has served on advisory boards for Janssen, Dendreon, Merck, GlaxoSmithKline, Lilly, Astellas, Genentech, Bristol-Myers Squibb, Novartis, Pfizer, EMD Serono, AstraZeneca, Seattle Genetics, Incyte, Aileron Therapeutics, Dracen, and Inovio Pharmaceuticals; has received research funding from Janssen, Dendreon, Novartis, Bristol-Myers Squibb, Merck, AstraZeneca, and Genentech/Roche; and is a cofounder of RAPPTA Therapeutics. ",
year = "2019",
month = jul,
doi = "10.1016/j.eururo.2019.04.004",
language = "English",
volume = "76",
pages = "82--83",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier B.V.",
number = "1",
}